Signature: Must comply with applicable digital signature laws like eIDAS (EU) or ESIGN (USA).

Documentation and Storage: A copy of the signed form must be provided to the subject and retained securely.

Regulatory Approval: Ethics Committees/IRBs must pre-approve the teleconsultation consent method.

Teleconsultation vs. Traditional Informed Consent:

The two methods share common ethical foundations but differ in execution:

Traditional Consent	Teleconsultation Consent
In-person investigator-subject interaction	Video/audio communication over secure platform
Wet-ink signature	Digital/electronic signature with timestamp
On-site documentation storage	Cloud-based or eTMF storage with audit trails

Teleconsultation Consent Workflow:

1. Pre-screen patient and schedule teleconsultation via secure platform
2. Provide access to Participant Information Sheet (PIS) and consent forms beforehand
3. Conduct real-time session with site PI or trained designee
4. Discuss study purpose, risks, alternatives, and address questions
5. Obtain electronic signature using validated eConsent system
6. Document the session: date, time, platform used, participants present
7. Store signed consent in the eISF and send copy to patient

Telehealth Platform Requirements:

To be used for informed consent, the telehealth platform must:

• Be GCP- and CSV validation protocol-compliant
• Enable screen sharing for form review
• Allow secure identity verification
• Log all interactions and timestamps
• Be approved by Ethics Committees and included in protocol appendices

Regulatory Guidance and Regional Considerations:

• USFDA supports eConsent via teleconsultation as long as it maintains GCP standards
• EMA allows remote consent with auditability and security controls
• CDSCO permits remote consent in India with EC approval and SOP documentation

Protocol sections related to consent must clearly outline the use of telemedicine and the exact workflow involved.

Best Practices for Informed Consent via Teleconsultation:

• Train all investigators and site staff on remote consent SOPs
• Use templated scripts to maintain consistency in consent delivery
• Confirm participant understanding with open-ended questions
• Retain call recordings (if permitted) and written summaries
• Include language-specific forms and translators when required

Include relevant updates in your pharma SOP documentation and ensure version control of forms.

Common Compliance Pitfalls to Avoid:

• Conducting consent without two-way interaction
• Failure to verify participant identity
• Omitting timestamps and session metadata
• Non-validated eConsent tools
• Missing EC approvals for teleconsultation processes

When to Re-Consent Remotely:

Re-consent is often required for:

• Protocol amendments affecting safety or procedures
• Changes in Investigational Product (IP)
• Updated risk-benefit information
• Transition from in-person to remote visits

Use of teleconsultation for re-consent must follow the same legally compliant process as initial consent.

Integrating into Protocol and Monitoring Plans:

Teleconsultation-based consent should be:

• Defined in the protocol’s consent methodology section
• Included in the Monitoring Plan with centralized review of consent metadata
• Assessed during audits for SOP compliance and documentation completeness

Reference GMP compliance standards for document retention and traceability.

Conclusion:

Informed consent via teleconsultation, when executed correctly, offers an ethical, patient-friendly, and compliant method to enroll participants in decentralized clinical trials. By aligning with regional regulations, using validated platforms, and embedding robust procedures in SOPs and protocols, sponsors and CROs can streamline consent while maintaining trust and transparency. As technology evolves, remote consent will play a pivotal role in broadening trial access and reinforcing quality in modern research models.